A carregar...
Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury
Ambrisentan, an endothelin receptor type A antagonist, may be a novel therapeutic agent in neonatal chronic lung disease (CLD) by blocking the adverse effects of the vasoconstrictor endothelin-1, especially pulmonary arterial hypertension (PAH)-induced right ventricular hypertrophy (RVH). We determi...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Physiological Society
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3567362/ https://ncbi.nlm.nih.gov/pubmed/23292811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajplung.00073.2012 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|